Clinical trials
Carcinoma, Non-Small-Cell Lung (NSCLC) clinical trials
Below are recruiting carcinoma, non-small-cell lung (nsclc) clinical trials, each written for real people, not researchers. We’re tracking 78 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06400472RecruitingPhase 1
Study of LY4170156 for advanced solid tumors
This study tests a new drug called LY4170156 for people with certain advanced solid tumors. It aims to see if the drug is safe and how well it works.
Scottsdale, ArizonaAges 18 years+ - NCT06431633RecruitingPhase 3
Sacituzumab and zimberelimab for lung cancer after surgery
This trial tests a combination of two drugs (sacituzumab and zimberelimab) for people with non-small cell lung cancer that was confined to the chest, was surgically removed, but not completely cleared by prior chemotherapy and immunotherapy. The goal is to see if this treatment can help prevent the cancer from coming back.
Alicante, AlicanteAges 18 years+ - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Bullhead City, ArizonaAges 18 years+ - NCT06475937RecruitingPhase 1
DM001 for advanced solid tumors study
This study tests an experimental drug called DM001 for people with certain advanced cancers (breast, lung, stomach, gastroesophageal, or colorectal) that have not responded to or are not helped by standard treatments. The goal is to see if the drug is safe and how it affects the tumors.
Nashville, TennesseeAges 18 years+ - NCT06481813Recruiting
Lung Cancer Biobank Study for Newly Diagnosed Patients
This trial collects blood and tissue samples from people newly diagnosed with lung cancer (NSCLC or CPC) to study the disease over time. It helps researchers understand how different treatments affect the cancer and the body.
NantesAges 18 years+ - NCT06484491Recruiting
Higher-dose proton therapy for stage III lung cancer
This trial tests whether giving a higher dose of a special, precise form of radiation (proton therapy) to the main tumor can improve outcomes for people with stage III lung cancer who are already scheduled for chemoradiation and immunotherapy. It may help by targeting the tumor more effectively while protecting nearby organs.
GroningenAges 18 years+ - NCT06494540Recruiting
Study of TDC in advanced non-squamous lung cancer
This study looks at how well a targeted therapy called TDC works in people with a specific type of advanced lung cancer (non-squamous NSCLC) that has certain high-risk genetic changes. If you are starting TDC as your first treatment, this study may help track your progress and outcomes.
Bad HomburgAges 18–120 - NCT06566443RecruitingPhase 1
Honokiol for early-stage lung cancer before surgery
This trial tests a natural compound called honokiol in people with early-stage non-small cell lung cancer who are scheduled for surgery. The goal is to see if honokiol can help shrink or control the tumor before it is removed.
Houston, TexasAges 18 years+ - NCT06623487Recruiting
PET scan to guide immunotherapy for stage III lung cancer
This trial uses a special scan (68Ga-grazytracer PET) to see how well immunotherapy works for stage III non-small cell lung cancer before surgery or radiation. It aims to help doctors choose the best treatment for you.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06623656RecruitingPhase 2
Pre-surgery treatment comparison for non-small cell lung cancer
This trial compares two treatment approaches before surgery for non-small cell lung cancer (NSCLC): radiation plus immunotherapy versus chemotherapy plus immunotherapy. The goal is to see which combination works better to shrink the tumor before it is removed.
New York, New YorkAges 18 years+ - NCT06627738RecruitingPhase 2
Extra radiation boost for advanced lung cancer after standard treatment
This trial tests whether adding a precise, high-dose radiation boost (CyberKnife) after standard chemoradiation can improve outcomes for people with stage III non-small cell lung cancer that cannot be surgically removed. It is for those who have already completed two cycles of induction chemo and at least 40 Gy of radiation with chemo.
NiceAges 18 years+ - NCT06693336RecruitingPhase 2
Adjuvant chemotherapy trial for early-stage lung cancer
This trial tests a chemotherapy drug called SMS001 (a form of paclitaxel) after surgery for non-small cell lung cancer. It may help prevent the cancer from coming back.
Rochester, MinnesotaAges 18–80 - NCT06667908RecruitingPhase 2
Study of a drug with chemoradiation for stage 3 lung cancer
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
La Jolla, CaliforniaAges 18 years+ - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Huntsville, AlabamaAges 18 years+ - NCT06862869Recruiting
Alectinib after surgery for early ALK-positive lung cancer
This study looks at how well alectinib works when given after surgery to people with early-stage ALK-positive non-small cell lung cancer. It aims to understand real-world outcomes for patients who take this targeted therapy as their first treatment after surgery.
Zhanjiang, GuangdongAges 18 years+ - NCT07117214RecruitingPhase 1
Study of a new imaging agent for breast and lung cancers
This trial tests a new imaging agent called [68Ga]Ga-DWJ155 to see how well it helps detect certain types of advanced breast cancer and non-small cell lung cancer. It may help doctors better understand the cancer and guide treatment decisions.
Groningen, Provincie GroningenAges 18–100 - NCT06780085RecruitingPhase 2
Study of new drugs for advanced lung cancer
This trial tests new treatments for people with stage IV nonsquamous non-small cell lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It aims to find better options for those whose cancer has specific genetic features.
Lexington, KentuckyAges 18 years+ - NCT06709859RecruitingPhase 2
Afatinib plus chemo for unresectable stage III lung cancer
This trial tests whether combining afatinib (a targeted pill for EGFR mutations) with chemotherapy can shrink advanced stage III non-small cell lung cancer (NSCLC) enough to make surgery possible. It is for people whose cancer has not been treated yet and has a specific EGFR mutation.
Jinan, ShangdongAges 18 years+ - NCT06734182RecruitingPhase 2
Targeted therapy plus chemo before surgery for HER2-mutant lung cancer
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
GuangzhouAges 18–75 - NCT06833229Recruiting
Can a PET scan predict if immunotherapy is working?
This study uses a special PET-CT scan early in your treatment to see if immunotherapy (with or without chemotherapy) is working against your advanced lung cancer. The goal is to find out faster if the treatment is helping.
NiceAges 18 years+ - NCT06855771RecruitingPhase 2
Study of an oral drug for MTAP-deleted advanced lung cancer
This study tests an experimental oral medication (navlimetostat) for people with advanced lung cancer whose tumors have a specific genetic change called an MTAP deletion. It’s for those whose cancer has progressed after earlier treatments.
Anchorage, AlaskaAges 18 years+ - NCT06951464RecruitingPhase 2
Targeted therapy before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (BL-B01D1 and almonertinib) given before surgery to shrink EGFR-mutated lung cancer. The goal is to make surgery more effective and possibly improve long-term outcomes.
Chengdu, SichuanAges 18–75 - NCT06987734RecruitingPhase 2
Sugemalimab plus chemo before and after lung cancer surgery
This trial tests if adding the immunotherapy drug sugemalimab to standard chemotherapy before and after surgery can help people with stage II-IIIA non-small cell lung cancer. It aims to see if this combination reduces the chance of cancer coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Stanford, CaliforniaAges 18 years+
Hear when a new Carcinoma, Non-Small-Cell Lung (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma, non-small-cell lung (nsclc)?
- Yes. Clin2 currently lists 78 recruiting carcinoma, non-small-cell lung (nsclc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma, non-small-cell lung (nsclc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma, non-small-cell lung (nsclc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.